Phosphodiesterase
Phosphodiesterases (PDEs) are a family of phosphohydrolyases that catalyze the hydrolysis of 3' cyclic phosphate bonds in adenosine and/or guanine 3',5' cyclic monophosphate (cAMP and/or cGMP). PDEs regulate the second messengers by controlling their degradation.
Products for Phosphodiesterase
- Cat.No. Product Name Information/Activity
-
BCC2306
Anagrelide HCl
Anagrelide hydrochloride (BL4162A) is a drug used for the treatment of essential thrombocytosis.
-
BCC7940
BC 11-38
686770-80-9
-
BCN5807
Caffeine
58-08-2
-
BCC6173
Carbazeran citrate
153473-94-0
-
BCC7814
CDP 840 hydrochloride
Potent and selective PDE4 inhibitor
-
BCC7338
CGH 2466 dihydrochloride
Anti-inflammatory agent. Inhibitor of PDE4 and p38 MAPK, also adenosine receptor antagonist
-
BCC6843
Cilostamide
Cilostamide is a selective and potent PDE3 inhibitor, with IC50s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.
-
BCC2291
Cilostazol
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM.
-
BCC7155
Enoximone
77671-31-9
-
BCC6648
Etazolate hydrochloride
35838-58-5
